Mental ve Motor Regresyon
Özet
Mental ve motor regresyon (MMR), çocukluk döneminde daha önce kazanılmış bilişsel ve fiziksel yeteneklerin kademeli veya hızlı bir şekilde yitirilmesi olarak tanımlanır. Bu durum, yaygın gelişimsel gerilikten farklı olarak ilerleyici bir kayıp sürecine işaret eder ve erken tanı, geri dönüşümsüz hasarların önlenmesi ile tedavi edilebilir nörometabolik veya nörogenetik hastalıkların yönetimi açısından hayati önem taşır. Tanısal süreç, detaylı bir anamnez ve sistemik fizik muayene ile nörolojik olmayan dış etkenlerin elenmesini takiben, altta yatan metabolik veya dejeneratif nedenlerin sistematik araştırmasını gerektirir. Tedavi yaklaşımı ise semptomatik destek, palyatif bakım ve altta yatan spesifik etiyolojiye yönelik multidisipliner bir strateji üzerine kuruludur.
Mental and motor regression (MMR) is defined as the progressive loss of previously acquired cognitive and motor skills during childhood. Unlike global developmental delay, it involves a distinct decline, making early diagnosis critical for preventing irreversible damage and managing potentially treatable neurometabolic or neurogenetic conditions. The diagnostic process relies on a comprehensive medical history and physical examination to exclude non-neurological factors, followed by targeted investigations into underlying metabolic or degenerative causes. Management focuses on a multidisciplinary strategy, combining symptomatic support, palliative care, and specific interventions tailored to the underlying etiology.
Referanslar
Zhang D, Bedogni F, Boterberg S, et al. Towards a consensus on developmental regression. Neurosci Biobehav Rev. 2019;107:3-5. doi:10.1016/j.neubiorev.2019.08.014.
van Dommelen P, van Dijk O, de Wilde JA, Verkerk PH. Early developmental milestones in Duchenne muscular dystrophy. Dev Med Child Neurol. 2020;62(10):1198-1204. doi:10.1111/dmcn.14623.
Bélanger SA, Caron J. Evaluation of the child with global developmental delay and intellectual disability. Paediatr Child Health. 2018;23(6):403-419. doi:10.1093/pch/pxy093.
Yalaz K. Temel Gelişimsel Çocuk Nörolojisi. Pelikan Yayıncılık, Ankara. 2015. Pp 157-168.
Verity C, Winstone AM, Stellitano L, Will R, Nicoll A. The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child. 2010;95(5):361-364. doi:10.1136/adc.2009.173419.
Pierre G. Neurodegenerative disorders and metabolic disease. Arch Dis Child. 2013;98(8):618-624. doi:10.1136/archdischild-2012-302840.
Poletti V, Biffi A. Gene-Based Approaches to Inherited Neurometabolic Diseases. Hum Gene Ther. 2019;30(10):1222-1235. doi:10.1089/hum.2019.190.
van Karnebeek CD, Bowden K, Berry-Kravis E. Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. Pediatr Neurol. 2016;65:1-13. doi:10.1016/j.pediatrneurol.2016.07.010
Picker JD, Walsh CA. New innovations: therapeutic opportunities for intellectual disabilities. Annals of neurology. 2013;74(3):382–90. https://doi.org/10.1002/ana.24002.
Khan I, Leventhal BL. Developmental Delay. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 19, 2020.
Jimenez-Gomez A, Standridge SM. A refined approach to evaluating global developmental delay for the international medical community. Pediatr Neurol. 2014;51(2):198-206. doi:10.1016/j.pediatrneurol.2013.12.018.
Shevell M. Global developmental delay and mental retardation or intellectual disability: conceptualization, evaluation, and etiology. Pediatr Clin North Am. 2008;55(5):1071-xi. doi:10.1016/j.pcl.2008.07.010.
Pirozzi F, Nelson B, Mirzaa G. From microcephaly to megalencephaly: determinants of brain size. Dialogues Clin Neurosci. 2018;20(4):267-282. doi:10.31887/DCNS.2018.20.4/gmirzaa.
Winden KD, Yuskaitis CJ, Poduri A. Megalencephaly and Macrocephaly. Semin Neurol. 2015;35(3):277-287. doi:10.1055/s-0035-1552622.
Karimzadeh P. Approach to neurometabolic diseases from a pediatric neurological point of view. Iran J Child Neurol. 2015;9(1):1-16.
Al-Mosawi AJ. Clinical Genetics and Dysmorphology: Our Extraordinary Experiences. SunKrist J Neonat Pediatr. 2020;2(1):1009.
Jafari N, Golnik K, Shahriari M, Karimzadeh P, Jabbehdari S. Ophthalmologic Findings in Patients with Neuro-metabolic Disorders. J Ophthalmic Vis Res. 2018;13(1):34-38. doi:10.4103/jovr.jovr_242_16.
Fernandes J, Saudubray JM, Van den Berghe G, Walter JH. (Eds.). Inborn metabolic diseases: diagnosis and treatment. Springer Science & Business Media. 2006. Pp 189-193.
Smith T, Ram D. Fifteen-minute consultation: A practical approach to developmental regression in children. Arch Dis Child Educ Pract Ed. 2019;104(4):173-177. doi:10.1136/archdischild-2017-313792.
Holland J, Brown R. Developmental regression: assessment and investigation. Paediatrics and Child Health. 2017; 27(6): 253-59. DOI:https://doi.org/10.1016/j.paed.2017.01.013.
Sreekantam S, Wassmer E, An approach to developmental regression, Paediatrics and Child Health. 2013:23(6):273-77.
Bellman M, Byrne O, Sege R. Developmental assessment of children. BMJ. 2013;346:e8687. Published 2013 Jan 15. doi:10.1136/bmj.e8687.
Trivisano M, Specchio N. What are the epileptic encephalopathies?. Curr Opin Neurol. 2020;33(2):179-184. doi:10.1097/WCO.0000000000000793.
McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016;15(3):304-316. doi:10.1016/S1474-4422(15)00250-1.
Milh M, Cacciagli P, Ravix C, et al. Severe neonatal seizures: From molecular diagnosis to precision therapy?. Rev Neurol (Paris). 2016;172(3):171-173. doi:10.1016/j.neurol.2016.02.005.
Paciorkowski AR, Thio LL, Dobyns WB. Genetic and biologic classification of infantile spasms. Pediatr Neurol. 2011;45(6):355-367. doi:10.1016/j.pediatrneurol.2011.08.010.
Nordahl-Hansen A. Regression in autism is far more common than once thought. Neurosci Biobehav Rev. 2019;103:29-30. doi:10.1016/j.neubiorev.2019.06.023.
Burkett JG, Ailani J. An Up to Date Review of Pseudotumor Cerebri Syndrome. Curr Neurol Neurosci Rep. 2018;18(6):33. Published 2018 May 2. doi:10.1007/s11910-018-0839-1.
Mayans L. Lead Poisoning in Children. Am Fam Physician. 2019;100(1):24-30.
Lee JE, Min KR, Kim SH, Kim AH, Kim ST. Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital. Yonsei Med J. 2020;61(10):875-879. doi:10.3349/ymj.2020.61.10.875.
Mekki M, Eley B, Hardie D, Wilmshurst JM. Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol. 2019;61(10):1139-1144. doi:10.1111/dmcn.14166.
Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases [published correction appears in Nat Rev Dis Primers. 2018 Oct 18;4(1):36] [published correction appears in Nat Rev Dis Primers. 2019 May 17;5(1):34]. Nat Rev Dis Primers. 2018;4(1):27. Published 2018 Oct 1. doi:10.1038/s41572-018-0025-4.
McBride KL, Flanigan KM. Update in the Mucopolysaccharidoses. Semin Pediatr Neurol. 2021;37:100874. doi:10.1016/j.spen.2021.100874.
Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin. 2014;32(3):751-ix. doi:10.1016/j.ncl.2014.04.010.
Dozières-Puyravel B, Nasser H, Elmaleh-Bergès M, et al. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol. 2020;62(4):528-530. doi:10.1111/dmcn.14346.
Jo DS, Cho DH. Peroxisomal dysfunction in neurodegenerative diseases. Arch Pharm Res. 2019;42(5):393-406. doi:10.1007/s12272-019-01131-2.
Saudubray JM, Garcia-Cazorla A. An overview of inborn errors of metabolism affecting the brain: from neurodevelopment to neurodegenerative disorders. Dialogues Clin Neurosci. 2018;20(4):301-325. doi:10.31887/DCNS.2018.20.4/jmsaudubray.
Hayflick SJ, Kurian MA, Hogarth P. Neurodegeneration with brain iron accumulation. Handb Clin Neurol. 2018;147:293-305. doi:10.1016/B978-0-444-63233-3.00019-1.
Rangarh P, Kohli N. Neuroimaging findings in Menkes disease: a rare neurodegenerative disorder. BMJ Case Rep. 2018;2018:bcr2017223858. Published 2018 May 22. doi:10.1136/bcr-2017-223858.
Członkowska A, Litwin T, Chabik G. Wilson disease: neurologic features. Handb Clin Neurol. 2017;142:101-119. doi:10.1016/B978-0-444-63625-6.00010-0.
Saudubray JM, Garcia-Cazorla A. Inborn Errors of Metabolism Overview: Pathophysiology, Manifestations, Evaluation, and Management. Pediatr Clin North Am. 2018;65(2):179-208. doi:10.1016/j.pcl.2017.11.002.
Glasson EJ, Buckley N, Chen W, et al. Systematic Review and Meta-analysis: Mental Health in Children With Neurogenetic Disorders Associated With Intellectual Disability. J Am Acad Child Adolesc Psychiatry. 2020;59(9):1036-1048. doi:10.1016/j.jaac.2020.01.006.
Gold WA, Krishnarajy R, Ellaway C, Christodoulou J. Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities. ACS Chem Neurosci. 2018;9(2):167-176. doi:10.1021/acschemneuro.7b00346.
Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL et al. Swaiman's Pediatric Neurology E-Book: Principles and Practice. Elsevier Health Sciences. 2017. Pp e1029-1061.
Aydın K. Nörometabolik Hastalıklar, Olgularla Klinik ve Görüntüleme İpuçları. Medical Kitabevi. 2021. Pp 346-366.
Al Orf A, Waheed KB, Ali EM, et al. Inherited paediatric neurometabolic disorders, can brain magnetic resonance imaging predict?. Neurosciences (Riyadh). 2020;25(5):392-398. doi:10.17712/nsj.2020.5.20200072.
Sherr EH, Michelson DJ, Shevell MI, Moeschler JB, Gropman AL, Ashwal S. Neurodevelopmental disorders and genetic testing: current approaches and future advances. Ann Neurol. 2013;74(2):164-170. doi:10.1002/ana.23950.
Li M. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases. Pediatr Ann. 2018;47(5):e191-e197. doi:10.3928/19382359-20180424-01.
Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. 2017;120:63-80. doi:10.1016/j.neuropharm.2016.02.013.
Mastrangelo M. Clinical approach to neurodegenerative disorders in childhood: an updated overview [published correction appears in Acta Neurol Belg. 2019 Aug 26;:]. Acta Neurol Belg. 2019;119(4):511-521. doi:10.1007/s13760-019-01160-0.
